Neurofibromatosis Type 1:
An Overview

What is neurofibromatosis type 1 (NF1)?

Neurofibromatosis type 1 (NF1) is a rare genetic disorder caused by mutations in the NF1 gene, a gene responsible for the production of neurofibromin, a protein that acts as a brake in tumor development by keeping cells from growing too quickly. Absence or lack of neurofibromin results in a protein class called MEK1/MEK2 being overactive, causing rapid cell growth and increasing the risk of tumor development.

NF1 affects both children and adults and is often characterized by the presence of skin changes, such as café-au-lait (light brown) spots, tumor growth, bone abnormalities and neurological complications. NF1 symptoms and severity are different for each person.

What causes NF1?

In approximately 50% of cases, people inherit a mutated NF1 gene from a parent with NF1. In the other half of cases, people are born with a mutated NF1 gene even though neither of their parents has NF1. The mutated NF1 gene results in the absence or lack of neurofibromin.

What are plexiform neurofibromas (PN)?

Plexiform neurofibromas (PN) are a severe manifestation of NF1. They arise from peripheral nerves and can occur anywhere in the body, including the head and neck, extremities, areas around the spine, as well as deep in the body where they may affect organs. These tumors are characterized by aggressive growth, which is typically more rapid during childhood, and can cause severe pain, disfigurement, and debilitating loss of range of motion. PNs are non-malignant but in some patients (about 8-15%) they can evolve into a very severe and fatal malignant tumor called malignant peripheral nerve sheath tumors, or MPNST.

Who is at risk for NF1-associated plexiform neurofibromas (NF1-PN)?

It is estimated that NF1 affects 1 in 3,000 individuals worldwide and that there are approximately 100,000 people in the United States living with the disease. About 30-50% of people living with NF1 progress to develop NF1-PN. NF1-PN are most often diagnosed in the first two decades of life.

Clinical Representation of Neurofibromas

Cutaneous neurofibromas are benign tumors that develop within nerves and soft tissue of the skin. They may present as flat spots or as bumps and can cause itching, tingling pain, or cosmetic problems.

Plexiform neurofibromas are peripheral nerve sheath tumors that grow in an infiltrative pattern, making them challenging to surgically remove. They can cause severe disfigurement and pain, and unlike cutaneous neurofibromas, plexiform neurofibromas have the potential to turn into a malignant cancer.

How is NF1-PN treated?

Historically many people with NF1-PN were treated by having their tumors surgically removed; however, due to how these tumors grow on nerve cells it is challenging to successfully remove these tumors without serious complications, such as permanent nerve damage and further disfigurement.

SpringWorks is testing an investigational MEK inhibitor, mirdametinib, in a Phase 2b clinical trial, known as the ReNeu trial. Mirdametinib is under development as an oral, small molecule, selective inhibitor of MEK1 and MEK2, which play key roles in the MAPK signaling pathway—in other words, mirdametinib is designed to target a key pathway in the body that is known to play a role in many types of cancers and rare diseases.

ReNeu Trial Overview

What is the ReNeu trial?

The ReNeu trial is a Phase 2b clinical trial designed to evaluate the safety, effectiveness, and tolerability of an investigational medicine called mirdametinib in children 2 years or older and adults with an inoperable NF1-PN.

The ReNeu trial is an open-label study, meaning that both study participants and doctors are aware of the study treatment being given.

How long the study lasts:

Trial participation will last approximately 2 years.

How often you need to be seen as part of the trial:

Following an initial evaluation, participants will begin taking the study medication, which is available in a oral capsule or a pediatric formulation for children who cannot swallow a capsule. Participants will be asked to return to the clinic for study visits on a monthly basis for the first 7 months and then every other month until the end of the study, which is 2 years after the first dose of study treatment.

What happens at each clinic visit:

Each visit will include a routine evaluation such as a physical exam and a check of vital signs.

As part of the study, participants will also be asked to complete questionnaires, have MRI scans to measure their tumor, complete physical functioning assessments relevant to their plexiform neurofibroma(s), have photographs taken of their plexiform, complete eye exams to monitor their vision, have blood drawn, and adult participants will have a tumor biopsy. Participants will also undergo ECGs and echocardiograms, and may need to provide urine samples. There may be additional tests and physical assessments required as well. The clinical trial site will go over the details of the study with people who are eligible to participate and interested in enrolling in the ReNeu trial.

How Do I Know if My Child or I Qualify for the ReNeu Trial?

People who are interested in this study should discuss it with their doctor. Only a study doctor can determine if you or your loved one may meet the eligibility requirements, some of which include:

  • I have received a diagnosis of an NF1 and I have a PN that cannot be completely surgically removed that has a negative effect on my quality of life (e.g., trouble moving parts of your body, pain, disfigurement, etc.)
  • Me or my child is 2 years of age or older

How Do I Get Involved in the ReNeu Trial?

If you or a loved one is interested in participating in the ReNeu trial, please talk to your doctor to determine if you are eligible for this study.

For medical professionals seeking additional information about the ReNeu trial, please email

The ReNeu trial will be conducted in approximately 50 sites in the United States. Details of the trial locations can be found here.